The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: A registry-based study

Authors :: Brito dos Santos, Cleber Vinicius
Morais Valiati, Naiara Cristina
de Noronha, Tatiana Guimarães
Gomes Porto, Victor Bertollo
Pacheco, Antônio Guilherme
Freitas, Laís Picinini
Coelho, Flávio Codeço
da Costa Gomes, Marcelo Ferreira
Bastos, Leonardo Soares
Cruz, Oswaldo Gonçalves
Lana, Raquel Martins
Luz, Paula Mendes
Fagundes de Carvalho, Luiz Max
Werneck, Guilherme Loureiro
Struchiner, Claudio José
Maciel Villela, Daniel Antunes
Source :: The Lancet Regional Health - Americas; 20230101, Issue: Preprints
Publication Year :: 2023
Abstract: Brazil started the COVID-19 mass vaccination in January 2021 with CoronaVac and ChAdOx1, followed by BNT162b2 and Ad26.COV2.S vaccines. By the end of 2021, more than 317 million vaccine doses were administered in the adult population. This study aimed at estimating the effectiveness of the primary series of COVID-19 vaccination and booster shots in protecting against severe cases and deaths in Brazil during the first year of vaccination.

Full Text Access

Tools